Use of peginterferon alfa-2a (40 KD) (Pegasys®) for the treatment of hepatitis C-Reference-Cited by-同舟云学术

Use of peginterferon alfa-2a (40 KD) (Pegasys®) for the treatment of hepatitis C

Published:2002-06 Issue:4 Volume:54 Page:571-586
ISSN:0169-409X
Container-title:Advanced Drug Delivery Reviews
language:en
Short-container-title:Advanced Drug Delivery Reviews

Author:

Rajender Reddy K.,Modi Marlene W.,Pedder Simon

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference58 articles.

1. Pegylation: a novel process for modifying pharmacokinetics;Harris;Clin. Pharmacokinet.,2001

2. A branched methoxy 40 kDa polyethylene glycol (PEG) moiety optimizes the pharmacokinetics (PK) of peginterferon a-2a (PEG–IFN) and may explain its enhanced efficacy in chronic hepatitis C (CHC);Algranati;Hepatology,1999

3. Interferon kinetics and adverse reactions after intravenous, intramuscular, and subcutaneous injection;Wills;Clin. Pharmacol. Ther.,1984

4. Clinical pharmacokinetics of interferons;Wills;Clin. Pharmacokinet.,1990

5. Influence of human serum albumin content in formulations on the bioequivalency of interferon alfa-2a given by subcutaneous injection in healthy male volunteers;Zhi;J. Clin. Pharmacol,1995

Cited by 216 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Effect of PEGylation on Drugs’ Pharmacokinetic Parameters; from Absorption to Excretion;Current Drug Delivery;2024-08

2. Probing the Topological Effects on Stability Enhancement and Therapeutic Performance of Protein Bioconjugates: Tadpole, Macrocycle versus Figure‐of‐Eight;Advanced Healthcare Materials;2024-08

3. Revolutionizing Alzheimer's treatment: Harnessing human serum albumin for targeted drug delivery and therapy advancements;Ageing Research Reviews;2024-08

4. Approved delivery strategies for biopharmaceuticals;Chinese Chemical Letters;2024-07

5. Impact of PEG sensitization on the efficacy of PEG hydrogel-mediated tissue engineering;Nature Communications;2024-04-18